Bellevue Group AG - Significant Ownership

Signature - Title
/s/ Stefano Montalbano - Stefano Montalbano/ Chief Financial Officer
Location
Kuesnacht, Switzerland
Summary
This page shows a list of all the recent SCHEDULE 13D/G filings made by Bellevue Group AG.

Notify me when Bellevue Group AG files a new Schedule 13D/G report.

⭐ Subscribe ⭐

Significant Ownership of Bellevue Group AG

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
MGNX MacroGenics, Inc. Common Stock 15.7% $15.3M 9.93M Bellevue Group AG Jun 1, 2025
IMCR Immunocore Holdings plc Ordinary shares 5.6% $102M 2.8M Bellevue Group AG Aug 20, 2025
CLDX Celldex Therapeutics, Inc. Common Stock 5.4% $93.6M 3.62M Bellevue Group AG Aug 18, 2025
AGIO Agios Pharmaceuticals, Inc. Common Stock 0% $0 -$142M 0 -100% Bellevue Group AG Nov 19, 2025

Schedules 13D/G Reported by Bellevue Group AG:

Sym Target Class Ownership Change Current Shares Change Value Reporting name Form Report Period Date Filed
* An asterisk sign (*) next to the price indicates that the price is likely invalid.